当前位置: 首页 >> 检索结果
361. Conservative management versus tonsillectomy in adults with recurrent acute tonsillitis in the UK (NATTINA): a multicentre, open-label, randomised controlled trial.
作者: Janet A Wilson.;James O'Hara.;Tony Fouweather.;Tara Homer.;Deborah D Stocken.;Luke Vale.;Catherine Haighton.;Nikki Rousseau.;Rebecca Wilson.;Lorraine McSweeney.;Scott Wilkes.;Jill Morrison.;Kenneth MacKenzie.;Kim Ah-See.;Sean Carrie.;Claire Hopkins.;Nicola Howe.;Musheer Hussain.;Hisham Mehanna.;Christopher Raine.;Frank Sullivan.;Alexander von Wilamowitz-Moellendorff.;M Dawn Teare.
来源: Lancet. 2023年401卷10393期2051-2059页
Tonsillectomy is regularly performed in adults with acute tonsillitis, but with scarce evidence. A reduction in tonsillectomies has coincided with an increase in acute adult hospitalisation for tonsillitis complications. We aimed to assess the clinical effectiveness and cost-effectiveness of conservative management versus tonsillectomy in patients with recurrent acute tonsillitis.
362. Safety, effectiveness, and cost-effectiveness of immediate versus delayed sequential bilateral cataract surgery in the Netherlands (BICAT-NL study): a multicentre, non-inferiority, randomised controlled trial.
作者: Lindsay Spekreijse.;Rob Simons.;Bjorn Winkens.;Frank van den Biggelaar.;Carmen Dirksen.;Marjolijn Bartels.;Ronald de Crom.;Oege Goslings.;Maurits Joosse.;Jocelyn Kasanardjo.;Peter Lansink.;Theodorus Ponsioen.;Nic Reus.;Jan Schouten.;Rudy Nuijts.
来源: Lancet. 2023年401卷10392期1951-1962页
In an ageing population, efficiency improvements are required to assure future accessibility of cataract care. We aim to address remaining knowledge gaps by evaluating the safety, effectiveness, and cost-effectiveness of immediate sequential bilateral cataract surgery (ISBCS) versus delayed sequential bilateral cataract surgery (DSBCS). We hypothesised that ISBCS is non-inferior to DSBCS, regarding safety and effectiveness, and being superior in cost-effectiveness.
363. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial.
作者: Chantal Mathieu.;Björg Ásbjörnsdóttir.;Harpreet S Bajaj.;Wendy Lane.;Ana Laura S A Matos.;Sreenivasa Murthy.;Karolina Stachlewska.;Julio Rosenstock.
来源: Lancet. 2023年401卷10392期1929-1940页
Insulin icodec (icodec) is a basal insulin analogue suitable for once-weekly dosing. ONWARDS 4 aimed to assess the efficacy and safety of once-weekly icodec compared with once-daily insulin glargine U100 (glargine U100) in individuals with long-standing type 2 diabetes on a basal-bolus regimen.
364. Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): a randomised, controlled, three-arm, parallel group, phase 3, clinical trial.
作者: Peter Kent.;Terry Haines.;Peter O'Sullivan.;Anne Smith.;Amity Campbell.;Robert Schutze.;Stephanie Attwell.;J P Caneiro.;Robert Laird.;Kieran O'Sullivan.;Alison McGregor.;Jan Hartvigsen.;Den-Ching A Lee.;Alistair Vickery.;Mark Hancock.; .
来源: Lancet. 2023年401卷10391期1866-1877页
Low back pain is the leading cause of years lived with disability globally, but most interventions have only short-lasting, small to moderate effects. Cognitive functional therapy (CFT) is an individualised approach that targets unhelpful pain-related cognitions, emotions, and behaviours that contribute to pain and disability. Movement sensor biofeedback might enhance treatment effects. We aimed to compare the effectiveness and economic efficiency of CFT, delivered with or without movement sensor biofeedback, with usual care for patients with chronic, disabling low back pain.
365. A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial.
作者: Andrew W Bradbury.;Catherine A Moakes.;Matthew Popplewell.;Lewis Meecham.;Gareth R Bate.;Lisa Kelly.;Ian Chetter.;Athanasios Diamantopoulos.;Arul Ganeshan.;Jack Hall.;Simon Hobbs.;Kim Houlind.;Hugh Jarrett.;Suzanne Lockyer.;Jonas Malmstedt.;Jai V Patel.;Smitaa Patel.;S Tawqeer Rashid.;Athanasios Saratzis.;Gemma Slinn.;D Julian A Scott.;Hany Zayed.;Jonathan J Deeks.; .
来源: Lancet. 2023年401卷10390期1798-1809页
Chronic limb-threatening ischaemia is the severest manifestation of peripheral arterial disease and presents with ischaemic pain at rest or tissue loss (ulceration, gangrene, or both), or both. We compared the effectiveness of a vein bypass first with a best endovascular treatment first revascularisation strategy in terms of preventing major amputation and death in patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal, revascularisation procedure to restore limb perfusion.
366. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
作者: Harry P Erba.;Pau Montesinos.;Hee-Je Kim.;Elżbieta Patkowska.;Radovan Vrhovac.;Pavel Žák.;Po-Nan Wang.;Tsvetomir Mitov.;James Hanyok.;Yasser Mostafa Kamel.;Jaime E Connolly Rohrbach.;Li Liu.;Aziz Benzohra.;Arnaud Lesegretain.;Jorge Cortes.;Alexander E Perl.;Mikkael A Sekeres.;Hervé Dombret.;Sergio Amadori.;Jianxiang Wang.;Mark J Levis.;Richard F Schlenk.; .
来源: Lancet. 2023年401卷10388期1571-1583页
Patients with acute myeloid leukaemia (AML) positive for internal tandem duplication (ITD) mutations of FLT3 have poor outcomes. Quizartinib, an oral, highly potent, selective, type 2 FLT3 inhibitor, plus chemotherapy showed antitumour activity with an acceptable safety profile in patients with FLT3-ITD-positive newly diagnosed AML. The aim of the study was to compare the effect of quizartinib versus placebo on overall survival in patients with FLT3-ITD-positive newly diagnosed AML aged 18-75 years.
367. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial.
作者: Ornella Verrastro.;Simona Panunzi.;Lidia Castagneto-Gissey.;Andrea De Gaetano.;Erminia Lembo.;Esmeralda Capristo.;Caterina Guidone.;Giulia Angelini.;Francesco Pennestrì.;Luca Sessa.;Fabio Maria Vecchio.;Laura Riccardi.;Maria Assunta Zocco.;Ivo Boskoski.;James R Casella-Mariolo.;Pierluigi Marini.;Maurizio Pompili.;Giovanni Casella.;Enrico Fiori.;Francesco Rubino.;Stefan R Bornstein.;Marco Raffaelli.;Geltrude Mingrone.
来源: Lancet. 2023年401卷10390期1786-1797页
Observational studies suggest that bariatric-metabolic surgery might greatly improve non-alcoholic steatohepatitis (NASH). However, the efficacy of surgery on NASH has not yet been compared with the effects of lifestyle interventions and medical therapy in a randomised trial.
368. Ferric carboxymaltose versus standard-of-care oral iron to treat second-trimester anaemia in Malawian pregnant women: a randomised controlled trial.
作者: Sant-Rayn Pasricha.;Martin N Mwangi.;Ernest Moya.;Ricardo Ataide.;Glory Mzembe.;Rebecca Harding.;Truwah Zinenani.;Leila M Larson.;Ayse Y Demir.;William Nkhono.;Jobiba Chinkhumba.;Julie A Simpson.;Danielle Clucas.;William Stones.;Sabine Braat.;Kamija S Phiri.
来源: Lancet. 2023年401卷10388期1595-1609页
Anaemia affects 46% of pregnancies in Africa; oral iron is recommended by WHO but uptake and adherence are suboptimal. We tested a single dose of a modern intravenous iron formulation, ferric carboxymaltose, for anaemia treatment in Malawian pregnant women.
370. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
作者: Fabrice André.;Yeon Hee Park.;Sung-Bae Kim.;Toshimi Takano.;Seock-Ah Im.;Giuliano Borges.;Joao Paulo Lima.;Sercan Aksoy.;Joaquin Gavila Gregori.;Michelino De Laurentiis.;Giampaolo Bianchini.;Rebecca Roylance.;Yasuo Miyoshi.;Anne Armstrong.;Rajni Sinha.;Manuel Ruiz Borrego.;Elgene Lim.;Johannes Ettl.;Rinat Yerushalmi.;Flora Zagouri.;Francois P Duhoux.;Tanja Fehm.;Dhiraj Gambhire.;Jillian Cathcart.;Cai Wu.;Changan Chu.;Anton Egorov.;Ian Krop.
来源: Lancet. 2023年401卷10390期1773-1785页
In the single-arm, phase 2 DESTINY-Breast01 trial, trastuzumab deruxtecan showed robust activity in patients with HER2-positive metastatic breast cancer who were refractory or resistant to trastuzumab emtansine; a population with scarce effective treatments. In DESTINY-Breast02, we aimed to compare the efficacy and safety of trastuzumab deruxtecan with treatment of physician's choice in this patient population.
371. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
作者: Robin Kate Kelley.;Makoto Ueno.;Changhoon Yoo.;Richard S Finn.;Junji Furuse.;Zhenggang Ren.;Thomas Yau.;Heinz-Josef Klümpen.;Stephen L Chan.;Masato Ozaka.;Chris Verslype.;Mohamed Bouattour.;Joon Oh Park.;Olga Barajas.;Uwe Pelzer.;Juan W Valle.;Li Yu.;Usha Malhotra.;Abby B Siegel.;Julien Edeline.;Arndt Vogel.; .
来源: Lancet. 2023年401卷10391期1853-1865页
Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide. The standard-of-care treatment for advanced biliary tract cancer is chemotherapy with gemcitabine and cisplatin. Because most biliary tract cancers have an immune-suppressed microenvironment, immune checkpoint inhibitor monotherapy is associated with a low objective response rate. We aimed to assess whether adding the immune checkpoint inhibitor pembrolizumab to gemcitabine and cisplatin would improve outcomes compared with gemcitabine and cisplatin alone in patients with advanced biliary tract cancer.
372. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
作者: Kohei Shitara.;Florian Lordick.;Yung-Jue Bang.;Peter Enzinger.;David Ilson.;Manish A Shah.;Eric Van Cutsem.;Rui-Hua Xu.;Giuseppe Aprile.;Jianming Xu.;Joseph Chao.;Roberto Pazo-Cid.;Yoon-Koo Kang.;Jianning Yang.;Diarmuid Moran.;Pranob Bhattacharya.;Ahsan Arozullah.;Jung Wook Park.;Mok Oh.;Jaffer A Ajani.
来源: Lancet. 2023年401卷10389期1655-1668页
Zolbetuximab, a monoclonal antibody targeting claudin-18 isoform 2 (CLDN18.2), has shown efficacy in patients with CLDN18.2-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma. We report the results of the SPOTLIGHT trial, which investigated the efficacy and safety of first-line zolbetuximab plus mFOLFOX6 (modified folinic acid [or levofolinate], fluorouracil, and oxaliplatin regimen) versus placebo plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma.
373. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.
作者: Brett King.;Xingqi Zhang.;Walter Gubelin Harcha.;Jacek C Szepietowski.;Jerry Shapiro.;Charles Lynde.;Natasha A Mesinkovska.;Samuel H Zwillich.;Lynne Napatalung.;Dalia Wajsbrot.;Rana Fayyad.;Amy Freyman.;Debanjali Mitra.;Vivek Purohit.;Rodney Sinclair.;Robert Wolk.
来源: Lancet. 2023年401卷10387期1518-1529页
Alopecia areata is characterised by non-scarring loss of scalp, face, or body hair. We investigated the efficacy and safety of ritlecitinib, an oral, selective dual JAK3/TEC family kinase inhibitor, in patients with alopecia areata.
374. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
Low-dose corticosteroids have been shown to reduce mortality for patients with COVID-19 requiring oxygen or ventilatory support (non-invasive mechanical ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation). We evaluated the use of a higher dose of corticosteroids in this patient group.
375. The effect of vitamin B12 supplementation during pregnancy on infant growth and development in Nepal: a community-based, double-blind, randomised, placebo-controlled trial.
作者: Ram K Chandyo.;Ingrid Kvestad.;Manjeswori Ulak.;Suman Ranjitkar.;Mari Hysing.;Merina Shrestha.;Catherine Schwinger.;Adrian McCann.;Per M Ueland.;Sudha Basnet.;Laxman Shrestha.;Tor A Strand.
来源: Lancet. 2023年401卷10387期1508-1517页
Vitamin B12 is required for healthy infant growth and development, but low and marginal vitamin B12 status is endemic in low-income and middle-income countries. We aimed to measure the effect of vitamin B12 supplementation from early pregnancy until 6 months post partum on infant growth and neurodevelopment.
376. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
作者: Hiddo J L Heerspink.;Jai Radhakrishnan.;Charles E Alpers.;Jonathan Barratt.;Stewart Bieler.;Ulysses Diva.;Jula Inrig.;Radko Komers.;Alex Mercer.;Irene L Noronha.;Michelle N Rheault.;William Rote.;Brad Rovin.;Howard Trachtman.;Hernán Trimarchi.;Muh Geot Wong.;Vlado Perkovic.; .
来源: Lancet. 2023年401卷10388期1584-1594页
Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial in adults with IgA nephropathy. We report the prespecified interim analysis of the primary proteinuria efficacy endpoint, and safety.
377. Clinical outcomes of uninterrupted embryo culture with or without time-lapse-based embryo selection versus interrupted standard culture (SelecTIMO): a three-armed, multicentre, double-blind, randomised controlled trial.
作者: D C Kieslinger.;C G Vergouw.;L Ramos.;B Arends.;M H J M Curfs.;E Slappendel.;E H Kostelijk.;M H E C Pieters.;D Consten.;M O Verhoeven.;D E Besselink.;F Broekmans.;B J Cohlen.;J M J Smeenk.;S Mastenbroek.;C H de Koning.;Y M van Kasteren.;E Moll.;J van Disseldorp.;E A Brinkhuis.;E A M Kuijper.;W M van Baal.;H G I van Weering.;P J Q van der Linden.;M H Gerards.;P M Bossuyt.;M van Wely.;C B Lambalk.
来源: Lancet. 2023年401卷10386期1438-1446页
Time-lapse monitoring is increasingly used in fertility laboratories to culture and select embryos for transfer. This method is offered to couples with the promise of improving pregnancy chances, even though there is currently insufficient evidence for superior clinical results. We aimed to evaluate whether a potential improvement by time-lapse monitoring is caused by the time-lapse-based embryo selection method itself or the uninterrupted culture environment that is part of the system.
378. Endovascular treatment versus no endovascular treatment after 6-24 h in patients with ischaemic stroke and collateral flow on CT angiography (MR CLEAN-LATE) in the Netherlands: a multicentre, open-label, blinded-endpoint, randomised, controlled, phase 3 trial.
作者: Susanne G H Olthuis.;F Anne V Pirson.;Florentina M E Pinckaers.;Wouter H Hinsenveld.;Daan Nieboer.;Angelique Ceulemans.;Robrecht R M M Knapen.;M M Quirien Robbe.;Olvert A Berkhemer.;Marianne A A van Walderveen.;Geert J Lycklama À Nijeholt.;Maarten Uyttenboogaart.;Wouter J Schonewille.;P Matthijs van der Sluijs.;Lennard Wolff.;Henk van Voorst.;Alida A Postma.;Stefan D Roosendaal.;Anouk van der Hoorn.;Bart J Emmer.;Menno G M Krietemeijer.;Pieter-Jan van Doormaal.;Bob Roozenbeek.;Robert-Jan B Goldhoorn.;Julie Staals.;Inger R de Ridder.;Christiaan van der Leij.;Jonathan M Coutinho.;H Bart van der Worp.;Rob T H Lo.;Reinoud P H Bokkers.;Ewoud I van Dijk.;Hieronymus D Boogaarts.;Marieke J H Wermer.;Adriaan C G M van Es.;Julia H van Tuijl.;Hans G J Kortman.;Rob A R Gons.;Lonneke S F Yo.;Jan-Albert Vos.;Karlijn F de Laat.;Lukas C van Dijk.;Ido R van den Wijngaard.;Jeannette Hofmeijer.;Jasper M Martens.;Paul J A M Brouwers.;Tomas Bulut.;Michel J M Remmers.;Thijs E A M de Jong.;Heleen M den Hertog.;Boudewijn A A M van Hasselt.;Anouk D Rozeman.;Otto E H Elgersma.;Bas van der Veen.;Davy R Sudiono.;Hester F Lingsma.;Yvo B W E M Roos.;Charles B L M Majoie.;Aad van der Lugt.;Diederik W J Dippel.;Wim H van Zwam.;Robert J van Oostenbrugge.; .
来源: Lancet. 2023年401卷10385期1371-1380页
Endovascular treatment for anterior circulation ischaemic stroke is effective and safe within a 6 h window. MR CLEAN-LATE aimed to assess efficacy and safety of endovascular treatment for patients treated in the late window (6-24 h from symptom onset or last seen well) selected on the basis of the presence of collateral flow on CT angiography (CTA).
379. Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial.
作者: Guy Young.;Alok Srivastava.;Kaan Kavakli.;Cecil Ross.;Jameela Sathar.;Chur-Woo You.;Huyen Tran.;Jing Sun.;Runhui Wu.;Stacey Poloskey.;Zhiying Qiu.;Salim Kichou.;Shauna Andersson.;Baisong Mei.;Savita Rangarajan.
来源: Lancet. 2023年401卷10386期1427-1437页
Fitusiran, a subcutaneous investigational small interfering RNA therapeutic, targets antithrombin to rebalance haemostasis in people with haemophilia A or haemophilia B, irrespective of inhibitor status. We evaluated the efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors.
380. Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial.
作者: Roland Tschismarov.;Pierre Van Damme.;Clara Germain.;Ilse De Coster.;Mathieu Mateo.;Stephanie Reynard.;Alexandra Journeaux.;Yvonne Tomberger.;Kanchanamala Withanage.;Denise Haslwanter.;Katherine Terler.;Sabrina Schrauf.;Matthias Müllner.;Erich Tauber.;Katrin Ramsauer.;Sylvain Baize.
来源: Lancet. 2023年401卷10384期1267-1276页
Lassa fever is a substantial health burden in west Africa. We evaluated the safety, tolerability, and immunogenicity of a recombinant, live-attenuated, measles-vectored Lassa fever vaccine candidate (MV-LASV).
|